Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Haematologica ; 109(3): 835-845, 2024 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-37706363

RESUMEN

BTK inhibitors, Bcl-2 inhibitors, and other targeted therapies have significantly improved the outcomes of patients with chronic lymphocytic leukemia (CLL). With increased survivorship, monitoring disease and deciphering potential mechanisms of resistance to these agents are critical for devising effective treatment strategies. We used duplex sequencing, a technology that enables detection of mutations at ultra-low allelic frequencies, to identify mutations in five genes associated with drug resistance in CLL and followed their evolution in two patients who received multiple targeted therapies and ultimately developed disease progression on pirtobrutinib. In both patients we detected variants that expanded and reached significant cancer cell fractions (CCF). In patient R001, multiple known resistance mutations in both BTK and PLCG2 appeared following progression on zanubrutinib (BTK p.L528W, p.C481S; PLCG2 S707F, L845F, R665W, and D993H). In contrast, patient R002 developed multiple BTK mutations following acalabrutinib treatment, including known resistance mutations p.C481R, p.T474I and p.C481S. We found that pirtobrutinib was able to suppress, but not completely eradicate, BTK p.C481S mutations in both patients, but other resistance mutations such as mutations in PLCG2 and new BTK mutations increased while the patients were receiving pirtobrutinib. For example, BTK p.L528W in patient R001 increased in frequency more than 1,000-fold (from a CCF of 0.02% to 35%), and the CCF in p.T474I in patient R002 increased from 0.03% to 4.2% (more than 100-fold). Our data illuminate the evolutionary dynamics of resistant clones over the patients' disease course and under selective pressure from different targeted treatments.


Asunto(s)
Leucemia Linfocítica Crónica de Células B , Humanos , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Leucemia Linfocítica Crónica de Células B/genética , Mutación , Células Clonales , Frecuencia de los Genes
3.
Proc Natl Acad Sci U S A ; 112(15): 4797-802, 2015 Apr 14.
Artículo en Inglés | MEDLINE | ID: mdl-25825749

RESUMEN

Wnt signaling has a well-established role as a regulator of nervous system development, but its role in the maintenance and regulation of established synapses in the mature brain remains poorly understood. At excitatory glutamatergic synapses, NMDA receptors (NMDARs) have a fundamental role in synaptogenesis, synaptic plasticity, and learning and memory; however, it is not known what controls their number and subunit composition. Here we show that the receptor tyrosine kinase-like orphan receptor 2 (RoR2) functions as a Wnt receptor required to maintain basal NMDAR-mediated synaptic transmission. In addition, RoR2 activation by a noncanonical Wnt ligand activates PKC and JNK and acutely enhances NMDAR synaptic responses. Regulation of a key component of glutamatergic synapses through RoR2 provides a mechanism for Wnt signaling to modulate synaptic transmission, synaptic plasticity, and brain function acutely beyond embryonic development.


Asunto(s)
Receptores Huérfanos Similares al Receptor Tirosina Quinasa/metabolismo , Receptores de N-Metil-D-Aspartato/metabolismo , Transmisión Sináptica , Proteínas Wnt/metabolismo , Potenciales de Acción/fisiología , Animales , Células Cultivadas , Expresión Génica , Células HEK293 , Hipocampo/citología , Hipocampo/metabolismo , Humanos , Hibridación in Situ , Proteínas Quinasas JNK Activadas por Mitógenos/metabolismo , Microscopía Confocal , Técnicas de Placa-Clamp , Proteína Quinasa C/metabolismo , Células Piramidales/metabolismo , Células Piramidales/fisiología , Interferencia de ARN , Ratas , Receptores Huérfanos Similares al Receptor Tirosina Quinasa/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal , Proteínas Wnt/genética , Proteína Wnt-5a
4.
Oncogene ; 43(31): 2421-2430, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38918516

RESUMEN

Somatic TP53 mutations are prevalent in normal tissue but little is known about their association with cancer risk. Cervical liquid-based cytology (LBC), commonly known as Pap test, provides an accessible gynecological sample to test the value of TP53 somatic mutations as a biomarker for high-grade serous ovarian cancer (HGSC), a cancer type mostly driven by TP53 mutations. We used ultra-deep duplex sequencing to analyze TP53 mutations in LBC and blood samples from 70 individuals (30 with and 40 without HGSC) undergoing gynecologic surgery, 30 carrying BRCA1 or BRCA2 germline pathogenic variants (BRCApv). Only 30% of the tumor mutations were found in LBC samples. However, TP53 pathogenic mutations were identified in nearly all LBC and blood samples, with only 5.4% of mutations in LBC (20/368) also found in the corresponding blood sample. TP53 mutations were more abundant in LBC than in blood and increased with age in both sample types. BRCApv carriers with HGSC had more TP53 clonal expansions in LBC than BRCApv carriers without cancer. Our results show that, while not useful for direct cancer detection, LBC samples capture TP53 mutation burden in the gynecological tract, presenting potential value for cancer risk assessment in individuals at higher hereditary risk for ovarian cancer.


Asunto(s)
Proteína BRCA1 , Proteína BRCA2 , Mutación de Línea Germinal , Neoplasias Ováricas , Proteína p53 Supresora de Tumor , Humanos , Femenino , Proteína p53 Supresora de Tumor/genética , Mutación de Línea Germinal/genética , Neoplasias Ováricas/genética , Neoplasias Ováricas/sangre , Neoplasias Ováricas/patología , Neoplasias Ováricas/diagnóstico , Proteína BRCA2/genética , Persona de Mediana Edad , Proteína BRCA1/genética , Adulto , Anciano , Cuello del Útero/patología , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/sangre , Citología
5.
Geroscience ; 44(3): 1621-1639, 2022 06.
Artículo en Inglés | MEDLINE | ID: mdl-35416576

RESUMEN

We analyzed the effects of aging on protein abundance and acetylation, as well as the ability of the mitochondrial-targeted drugs elamipretide (SS-31) and nicotinamide mononucleotide (NMN) to reverse aging-associated changes in mouse hearts. Both drugs had a modest effect on restoring the abundance and acetylation of proteins that are altered with age, while also inducing additional changes. Age-related increases in protein acetylation were predominantly in mitochondrial pathways such as mitochondrial dysfunction, oxidative phosphorylation, and TCA cycle signaling. We further assessed how these age-related changes associated with diastolic function (Ea/Aa) and systolic function (fractional shortening under higher workload) measurements from echocardiography. These results identify a subset of protein abundance and acetylation changes in muscle, mitochondrial, and structural proteins that appear to be essential in regulating diastolic function in old hearts.


Asunto(s)
Mononucleótido de Nicotinamida , Proteoma , Animales , Ratones , Mitocondrias/metabolismo , Mononucleótido de Nicotinamida/farmacología , Oligopéptidos/metabolismo , Oligopéptidos/farmacología , Proteoma/metabolismo , Proteoma/farmacología
6.
Cell Rep ; 21(1): 60-69, 2017 Oct 03.
Artículo en Inglés | MEDLINE | ID: mdl-28978484

RESUMEN

Wnt signaling controls multiple biological process, particularly the embryonic development of metazoans. Sustained expression of Wnt signaling components in the mature mammalian CNS and their apparent deregulation in certain neuropathologies suggest that it also plays a part beyond embryonic development to regulate normal brain function. We describe a noncanonical Wnt/Ca2+ signaling cascade that regulates the electrophysiological intrinsic properties of rat neurons, resulting in sustained membrane depolarization and the mobilization of Ca2+ from internal stores. These effects require tyrosine kinase-like orphan receptor 2 (RoR2), activation of PLC, and voltage-gated Ca2+ channels. Activation of this signaling cascade then promotes surface expression of N-methyl-D-aspartate receptors (NMDARs) through a SNARE-dependent mechanism. This neuronal Wnt/Ca2+ signaling pathway represents a mechanism for Wnt ligands to regulate normal brain processes in the mature animal and provides a framework for understanding how alterations in this pathway may contribute to the etiology of psychiatric disorders where NMDARs are compromised.


Asunto(s)
Señalización del Calcio , Hipocampo/metabolismo , Neuronas/metabolismo , Receptores de N-Metil-D-Aspartato/genética , Vía de Señalización Wnt , Potenciales de Acción/fisiología , Animales , Canales de Calcio Tipo N/genética , Canales de Calcio Tipo N/metabolismo , Femenino , Regulación de la Expresión Génica , Células HEK293 , Hipocampo/citología , Humanos , Masculino , Microtomía , Neuronas/citología , Técnicas de Placa-Clamp , Transporte de Proteínas , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores Huérfanos Similares al Receptor Tirosina Quinasa/deficiencia , Receptores Huérfanos Similares al Receptor Tirosina Quinasa/genética , Receptores de N-Metil-D-Aspartato/metabolismo , Técnicas de Cultivo de Tejidos , Fosfolipasas de Tipo C/genética , Fosfolipasas de Tipo C/metabolismo , Proteínas Wnt/genética , Proteínas Wnt/metabolismo , Proteína Wnt-5a/genética , Proteína Wnt-5a/metabolismo
7.
J Biophotonics ; 3(5-6): 328-35, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20376860

RESUMEN

A murine model of cutaneous leishmaniasis with green fluorescent protein positive (GFP+) L. major enables the monitoring of parasitic load via measurements of GFP fluorescence intensity, allowing for a faster and more efficient way of monitoring the clinical outcome of photodynamic therapy (PDT). This model may provide new insights on the phototoxic aspects in PDT. Although PDT regimens may be somewhat different in humans, it is expected that the developed model will facilitate the optimization and clinical translation of PDT as a therapy for cutaneous leishmaniasis and the eventual development of topical PDT treatments for other granulomatous infections.


Asunto(s)
Leishmania major/efectos de los fármacos , Leishmaniasis Cutánea/tratamiento farmacológico , Fenotiazinas/uso terapéutico , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/uso terapéutico , Animales , Calibración , Modelos Animales de Enfermedad , Enfermedades del Oído/tratamiento farmacológico , Enfermedades del Oído/parasitología , Femenino , Fluorescencia , Proteínas Fluorescentes Verdes , Leishmania major/metabolismo , Leishmaniasis Cutánea/parasitología , Ratones , Ratones Endogámicos BALB C , Fenotiazinas/farmacología , Fármacos Fotosensibilizantes/farmacología , Reproducibilidad de los Resultados , Transfección , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA